3,6-diamino-N²,N⁵-bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)pyrazine-2,5-dicarboxamide | 960510-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3,6-diamino-N²,N⁵-bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)pyrazine-2,5-dicarboxamide
• 英文别名: 3,6-diamino-2-N,5-N-bis[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]pyrazine-2,5-dicarboxamide
• CAS: 960510-28-5
• 化学式: C₁₈H₂₈N₆O₆
• 分子量: 424.457
• InChiKey: RUFYGCSAYMPMJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  173
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  3,6-diamino-N²,N⁵-bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)pyrazine-2,5-dicarboxamide 在 盐酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 、 1,2-二氯乙烷 为溶剂， 反应 27.0h， 生成 N2,N5-bis(2,3-dihydroxypropyl)-3,6-bis[(R)-2,3-dihydroxypropylamino]pyrazine-2,5-dicarboxamide
  参考文献：
  名称：

  Hydrophilic Pyrazine Dyes as Exogenous Fluorescent Tracer Agents for Real-Time Point-of-Care Measurement of Glomerular Filtration Rate

  摘要：

  Various hydrophilic pyrazine-bis(carboxamides) derived from 3,5-diamino-pyrazine-2,5-dicarboxylic acid bearing neutral and anionic groups were prepared and evaluated for use as fluorescent glomerular filtration rate (GFR) tracer agents. Among these, the dianionic D-serine pyrazine derivatives 2d and 2j, and the neutral dihydroxypropyl 2h, exhibited favorable physicochemical and clearance properties. In vitro studies show that 2d, 2h, and 2j have low plasma protein binding, a necessary condition for renal excretion. In vivo animal model results show that these three compounds exhibit a plasma clearance equivalent to iothalamate (a commonly considered gold standard GFR agent). In addition, these compounds have a higher urine recovery compared to iothalamate. Finally, the plasma clearance of 2d, 2h, and 2j remained unchanged upon blockage of the tubular secretion pathway with probenecid, a necessary condition for establishment of clearance via glomerular filtration only. Hence, 2d, 2h, and 2j are promising candidates for translation to the clinic as exogenous fluorescent tracer agents in real-time point-of-care monitoring of GFR.

  DOI：

  10.1021/jm200257k
• 作为产物：
  描述：

  dipotassium 2,4,6,8-tetrahydroxypyrimido(4,5-g)pteridine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~170.0 ℃ 、790.82 kPa 条件下， 反应 18.0h， 生成 3,6-diamino-N²,N⁵-bis((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)pyrazine-2,5-dicarboxamide
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE
  [FR] COMPOSITIONS ET MÉTHODES POUR ÉVALUER LE SYSTÈME VASCULAIRE DE L'ŒIL

  摘要：

  本公开涉及用于评估人体血管和器官的组合物和方法，更具体地说是用于评估眼部血管的方法。

  公开号：

  WO2016183351A1

文献信息

• METHODS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125902A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定肾小球滤过率或评估患者肾功能的系统和方法。该方法包括向患者施用化合物I的吡嗪类化合物，并监测患者的肾脏从患者的全身循环中排除吡嗪的速率。当暴露于电磁辐射时，吡嗪化合物会发出荧光，使用一个或多个传感器来检测。患者体内荧光减少的速率被用来计算患者的肾小球滤过率。
• COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125901A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及确定肾小球滤过率或评估需要的患者的肾功能的系统和方法。该系统包括计算设备、电源、一个或多个传感器，以及至少一种示踪剂，当暴露于电磁辐射时发出荧光。传感器检测电磁辐射，患者体内荧光减弱的速率用于计算患者的肾小球滤过率。
• [EN] MODIFIED PYRAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS MODIFIÉS DE PYRAZINE ET LEURS UTILISATIONS
  申请人：MALLINCKRODT INC

  公开号：WO2010078025A1

  公开（公告）日：2010-07-08

  Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.

  本文提供了含有多个聚乙二醇取代基的吡嗪衍生物的化合物、制剂和配方。其中许多化合物可通过受试者或患者的肾系统排泄，并可用于可视化受试者或患者的肾系统。在电磁辐射的激发下，本文披露的一些化合物表现出发光性，并在患者或受试者的体液中存在时可外部检测到。本文还提供了可视化受试者或患者的肾系统的方法。
• Pyrazine Derivatives and Uses Thereof in Renal Monitoring
  申请人：Rajagopalan Raghavan

  公开号：US20120100078A1

  公开（公告）日：2012-04-26

  The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X 1 to X 4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y 1 to Y 4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

  本发明涉及吡嗪衍生物，如下式I和II所示。化合物的X1到X4可以被表征为电子吸引基团。相反，化合物的Y1到Y4可以被表征为电子供给基团。本发明的吡嗪衍生物可用于评估肾功能。特别地，可以将本发明的吡嗪衍生物的有效量注入患者体内。体内的吡嗪衍生物可以暴露于可见光和/或红外光以使其发出光谱能量。可以检测和利用这种发出的光谱能量来确定患者的肾功能。
• Modified Pyrazine Derivatives and Uses Thereof
  申请人：Poreddy Amruta

  公开号：US20140186267A1

  公开（公告）日：2014-07-03

  Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.

  本文提供了含有多个聚乙二醇取代基的吡嗪衍生物的化合物、制剂和配方。本文披露的许多化合物可被患者的肾系统排泄，并可用于可视化患者的肾系统。在电磁辐射的激发下，本文披露的一些化合物表现出发光性，并在患者或受试者的体液中存在时可外部检测。本文还提供了可视化受试者或患者肾系统的方法。